drugset / Trial / NCT04923542
SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases
Phase 1/2
Recruiting
31 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Eli Lilly and Company · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a single arm study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) among patients with hormone receptor (HR)+/HER2- metastatic breast cancer brain metastases.
Timeline
- Start
- 2021-11-30
- Primary completion
- 2027-07
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 150 mg | Oral |
| Background | Fulvestrant | Small molecule | — | — |